Skip to main content
Premium Trial:

Request an Annual Quote

David Ichikawa, Michael Treble, Sren Brunak, John Sulston, Anna Tramontano, Martin Vingron, Gunnar von Heijne, and Allen Ruzycki


Sangamo BioSciences said this week that David Ichikawa has been named as the company’s senior vice president of business development.

Ichikawa will be responsible for all licensing and business development activities for the company and will report to Sangamo President and CEO Edward Lanphier.

Ichikawa was most recently CBO for Sagres Discovery, where he was responsible for corporate strategy and business development activities, said Sangamo. Prior to this, he held several positions with Chiron including vice president of R&D, business development, and finance.

Ichikawa holds an MBA from the University of California, Berkeley and a BS from the University of California, Davis.

Isis Pharmaceuticals said this week that Michael Treble has joined the company as CEO of its Ibis program.

The Ibis program is focused on developing a platform technology that can rapidly and accurately identify a broad range of organisms in a single test and to develop small molecule antibacterial and antiviral drugs that bind to RNA, according to Isis.

Treble was a founder of Tienta Sciences and SonoPlot, two start-up companies based on technology licensing applications from Purdue University and Wisconsin University. Prior to this, Treble was president and CEO of NimbleGen Systems, said Isis. He was also was also executive vice president, COO, and director of Third Wave Technologies.

Treble holds an MBA from the University of Buffalo and a BS from Canisius College.

The European Molecular Biology Laboratory has established a Bioinformatics Advisory Committee.

Members of the committee include Søren Brunak (Chairman) of the Technical University of Denmark, John Sulston of the Wellcome Trust Sanger Institute, Anna Tramontano of the University of RomeLa Sapienza,” Martin Vingron of the Max Planck Institute for Molecular Genetics, and Gunnar von Heijne of Stockholm University.

Allen Ruzycki has joined Phyton Biotech, a subsidiary of Fort Worth, Texas-based DFB Pharmaceuticals, as director of finance and administration, the company said last week. Most recently, he was acting director of finance for an unnamed privately held company, Phyton said.

He has also been employed by Nabisco, Fisher Scientific, Poly Chrome, and BASF Corporation.

Ruzycki holds a BA in finance from Drexel University and an MBA in finance from Fairleigh Dickinson University.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.